<DOC>
	<DOCNO>NCT02173652</DOCNO>
	<brief_summary>The objective investigate influence 2 different dosage regimen ( 5 mg daily vs. 2.5 mg twice daily ) steady-state pharmacokinetics pharmacodynamics orally administer BI 1356 .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Multiple 5 mg Doses BI 1356 p.o . Given Once Daily Compared Multiple 2.5 mg Doses Given Twice Daily Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy female male base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥18 Age ≤65 year BMI ≥18.5 BMI ≤29.9 kg/m² ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection ( e.g . HIV ) History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For male subject : Not willing use adequate contraception ( condome use plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , IUD ( intrauterine device ) ) whole study period time first intake study drug one month last intake For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test Are willing unable use reliable method contraception ( implant , injectibles combine oral contraceptive , sterilisation , IUD , double barrier method ) least 3 month prior participation trial , 2 month completion/termination trial Chronic use oral contraception hormone replacement contain ethinyl estradiol method contraception Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>